Premium
Can we screen high‐risk individuals to detect early pancreatic carcinoma?
Author(s) -
Goggins Michael,
Canto Mimi,
Hruban Ralph
Publication year - 2000
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/1096-9098(200008)74:4<243::aid-jso1>3.0.co;2-c
Subject(s) - medicine , pancreatic cancer , germline mutation , pancreatic disease , disease , pancreas , cancer , oncology , gastroenterology , mutation , gene , genetics , biology
An estimated 10% of individuals with pancreatic cancer have an inherited predisposition to the disease. Germline mutations in BRCA2, p16, STK11, and the cationic trypsinogen gene contribute to inherited forms of pancreatic cancer, but the gene(s) responsible for much of the familial pancreatic cancer burden remains to be identified. The high lifetime risk of pancreatic cancer that exists among at‐risk members of families with multiple pancreatic cancers highlights the pressing need for pancreatic cancer early detection strategies. Since curative pancreatic resection is still the only curative treatment for most patients with pancreatic cancer, the early detection of symptomless pancreatic cancer using endoscopic ultrasound or molecular markers may provide the best chance of cure for individuals at high risk of this disease. J. Surg. Oncol. 2000:74:243–248. © 2000 Wiley‐Liss, Inc.